InvestSMART

InhaleRx Limited (ASX:IRX)

ALERT: Price-sensitive ASX Announcement for IRX
Current share price for IRX : $0.028 0.004 (16.67%)+
Announcement
Release
29 Jan 2026 1:25PM
Price at Release
$0.024
Full Release
download
Summary
InhaleRx Limited's quarterly report for the period ended 31 December 2025 details the ongoing development of its three key drugs: IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder, and SRX-25 for treatment-resistant depression. The company is focused on advancing clinical trials to achieve FDA approval while securing significant funding from the Linlithgow Family Office. Operational highlights include the completion of drug manufacturing for trials, execution of Clinical Trial Research Agreements, and the resolution of budget negotiations to facilitate trial progress. The report also outlines financial activities, including a capital raise through placement and entitlement offers to fund operations, and the company's strategic plans for rebranding to better reflect its expanded focus on drug development.
Key Points
  • Completion of $750,000 placement and $107,730 entitlement offer for operational costs.
  • Funding agreement extension of $12.6 million with Linlithgow Family Office for SRX-25 development.
  • Manufacturing completion for IRX-211 and IRX-616a trial drugs.
  • IRX-211 Phase 2 trial preparation, including site agreements and initiation visits.
  • IRX-616a Phase 1 trial agreements and manufacturing finalization.
  • Significant progress on SRX-25 Phase 1 trial protocol and investigator brochure.
  • Dec25 clinical development costs totaled $485k with funding support from Clendon/LFO.
  • Rebranding to Nexalis Therapeutics Limited pending shareholder approval.
  • Aim to secure FDA NDA approvals using cost-effective regulatory pathways.
  • Strategic focus on addressing unmet medical needs in pain and mental health.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.